Ocular Therapeutics said its Phase III trial of X-Paxly showed superiority over an anti-VEGF with a p-value of less than 0.0006. The company expects to submit the NDA in the fourth quarter of this year. It also moved the SOL-R primary endpoint to week 40 from week 56.
OCUL · Ocular Therapeutix, Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Ocular remains on track to submit X-Paxley’s wet AMD NDA in the fourth quarter and moved SOLAR’s primary endpoint from week 56 to week 40, preserving trial integrity. It ended the third quarter with $530.6 million in cash.
Ocular Therapeutix elected Riad Sherif to its Board effective November 6, 2026, as a Class I director until the 2027 annual meeting. Seung Suh Hong resigned effective December 31, 2026, with no disagreement over operations, policies or practices.
Ocular Therapeutix said AXPAXLI met SOL-1’s Week 36 primary endpoint, with 74.1% maintaining visual acuity versus 55.8% for aflibercept 2 mg. At Week 52, 65.9% maintained visual acuity versus 44.2%.
Ocular Therapeutix, Inc. said its AXPAXLI wet AMD NDA submission remains on track for 4Q 2026 under 505(b)(2), with $530.6 million cash and expected runway into 2028. Third-quarter revenue was $12.9 million and net loss was $(94.8) million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 9, 2026TL;DR. AXPAXLI’s wet AMD NDA remains on track for 4Q 2026 with FDA alignment, and the 505(b)(2) pathway could shorten review by up to 60 days. SOL-1 demonstrated superiority, SOL-R’s Week 40 endpoint change preserves trial integrity, and SOL-X will evaluate 48-week dosing. Revenue declined, operating expenses increased, and net loss widened; cash provides a runway into 2028 but excludes full manufacturing scale-up and commercial-team costs if AXPAXLI is approved.
- + SOL-1 met its superiority primary endpoint, with 74.1% of AXPAXLI-treated subjects maintaining vision at Week 36.
- + SOL-1 post hoc analysis showed sustained anatomical control, with approximately 70% of subjects who were dry at Week 8 remaining dry through Week 36 after one injection.
- + SOL-R’s primary endpoint was moved to Week 40 so all subjects could complete efficacy assessments before the Week 52 interim safety analysis, preserving trial integrity.
- + Ocular plans to modify SOL-X to evaluate AXPAXLI dosing every 48 weeks based on demonstrated durability.
- − Research and development expense increased to $74.8 million from $52.4 million, driven by faster enrollment and expanded clinical infrastructure.
- − The cash-runway projection excludes the full costs of manufacturing scale-up and commercial staffing if AXPAXLI is approved.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Customer 1 | 43% | Three Months Ended June 30, 2026 filing | — |
| Customer 2 | 25% | Three Months Ended June 30, 2026 filing | — |
| Customer 3 | 6% | Three Months Ended June 30, 2026 filing | — |
| Direct research and development expenses for our products and product candidates | 29.5M | the three months ended June 30, 2026 filing | — |
| GTN Provisions as a percentage of gross DEXTENZA product sales | 55% | the three months ended June 30, 2026 filing | — |
| In-Market Sales | 50,000 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OCUL
this stock
Ocular Therapeutix, Inc
|
$1.31B | -51.1% | +3.5% | — | 13.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 19
Ocular Therapeutics said its Phase III trial of X-Paxly showed superiority over an anti-VEGF with a p-value of less than 0.0006. The company expects to submit the NDA in the fourth quarter of this year. It also moved the SOL-R primary endpoint to week 40 from week 56.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OCUL | -10.8% | -8.3% | -34.1% | -14.8% | -51.1% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -6.9% | -2.8% | -30.6% | -11.4% | -58.2% |